Merus N.V. (MRUS) – Analyst Ratings
-
Truist Securities Starts Merus N.V. (MRUS) at Buy, 'there is more upside on Peto's 2 clinical catalysts'
-
Merus N.V. (MRUS) PT Raised to $58 at BMO Capital
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MRUS Stock Lookup